Harvard Bioscience Inc (HBIO) concluded trading on Thursday at a closing price of $0.67, with 630.81 million shares of worth about $422.64 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -70.48% during that period and on May 29, 2025 the price saw a gain of about 135.74%. Currently the company’s common shares owned by public are about 44.21M shares, out of which, 37.41M shares are available for trading.
Stock saw a price change of 105.46% in past 5 days and over the past one month there was a price change of 81.18%. Year-to-date (YTD), HBIO shares are showing a performance of -68.24% which decreased to -78.79% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.28 but also hit the highest price of $3.60 during that period. The average intraday trading volume for Harvard Bioscience Inc shares is 644.50K. The stock is currently trading 91.55% above its 20-day simple moving average (SMA20), while that difference is up 58.05% for SMA50 and it goes to -60.43% lower than SMA200.
Harvard Bioscience Inc (NASDAQ: HBIO) currently have 44.21M outstanding shares and institutions hold larger chunk of about 60.30% of that.
The stock has a current market capitalization of $29.63M and its 3Y-monthly beta is at 1.38. It has posted earnings per share of -$1.32 in the same period. It has Quick Ratio of 0.40 while making debt-to-equity ratio of 3.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HBIO, volatility over the week remained 48.15% while standing at 21.03% over the month.
Analysts are in expectations that Harvard Bioscience Inc (HBIO) stock would likely to be making an EPS of -0.03 in the current quarter, while forecast for next quarter EPS is 0.01 and it is 0.06 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.03 which is -0.02 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 0.0 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 16.67% while it is estimated to increase by 71.43% in next year.
Coverage by The Benchmark Company stated Harvard Bioscience Inc (HBIO) stock as a Buy in their note to investors on March 10, 2023, suggesting a price target of $4 for the stock. On January 07, 2021, The Benchmark Company Upgrade their recommendations, while on December 09, 2020, Northland Capital Initiated their ratings for the stock with a price target of $6. Stock get an Overweight rating from KeyBanc Capital Markets on November 10, 2020.
